Human trials confirmed that LC n-3 PUFA from either fish or fish oil supplements as well as ALA enrichment significantly reduce blood triglyceride levels in patients with MetS in a dose-dependent manner [35, 68], an effect that appears to be mediated through inhibition of hormonesensitive lipase and VLDL secretion, and increase in apo B liver degradation [35].